Insider Trading Arrangements |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
shares
| |
| Trading Arrangements, by Individual | |
| Non-Rule 10b5-1 Arrangement Adopted | false |
| Rule 10b5-1 Arrangement Terminated | false |
| Non-Rule 10b5-1 Arrangement Terminated | false |
| Dr. Kristian Reich [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On March 10, 2026, Dr. Kristian Reich, the Chief Scientific Officer of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b-1(c). Dr. Reich's plan provides for the sale, subject to certain conditions, of up to 450,000 Class A Ordinary Shares through November 24, 2026.
|
| Name | Dr. Kristian Reich |
| Title | Chief Scientific Officer |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 10, 2026 |
| Expiration Date | November 24, 2026 |
| Arrangement Duration | 259 days |
| Aggregate Available | 450,000 |
| Dr. Jorge Santos da Silva [Member] | |
| Trading Arrangements, by Individual | |
| Material Terms of Trading Arrangement | On March 31, 2026, Dr. Jorge Santos da Silva, the Chief Executive Officer and a director of the Company, adopted a trading plan intended to satisfy the affirmative defense of Rule 10b-1(c). Dr. Santos da Silva's plan provides for the sale, subject to certain conditions, of up to 150,000 Class A Ordinary Shares through July 31, 2026.
|
| Name | Dr. Jorge Santos da Silva |
| Title | Chief Executive Officer and a director |
| Rule 10b5-1 Arrangement Adopted | true |
| Adoption Date | March 31, 2026 |
| Expiration Date | July 31, 2026 |
| Arrangement Duration | 122 days |
| Aggregate Available | 150,000 |